# Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

> **NCT06672536** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 82 (estimated)

## Conditions studied

- nAMD

## Interventions

- **DRUG:** SCT520FF
- **DRUG:** SCT520FF
- **DRUG:** SCT520FF
- **DRUG:** EYLEA 2 MG

## Key facts

- **NCT ID:** NCT06672536
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-26
- **Primary completion:** 2026-09-23
- **Final completion:** 2027-01-11
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672536, "Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06672536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*